{
    "title": "Eisai to receive royalties instead of profits from Alzheimer's drug Aduhelm",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10613281/Eisai-receive-royalties-instead-profits-Alzheimers-drug-Aduhelm.html",
    "date": "2022-03-15",
    "keywords": [
        "drug",
        "biogen",
        "treatment",
        "year",
        "aduhelm",
        "fda",
        "panel",
        "december",
        "march",
        "ltd",
        "share",
        "profit",
        "partner",
        "inc",
        "monday",
        "eisai",
        "statement",
        "decision",
        "making",
        "commercialization",
        "food",
        "administration",
        "june",
        "benefit",
        "expert",
        "price",
        "wake",
        "developer",
        "supply",
        "agreement",
        "focus",
        "lecanemab",
        "option",
        "haruo",
        "naito",
        "eisais",
        "executive",
        "officer",
        "manner",
        "protein",
        "beta",
        "disease",
        "impact",
        "designation",
        "reporting",
        "shubham",
        "sharma",
        "bengaluru",
        "editing",
        "subhranshu",
        "sahu"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}